Changes in these processes generate surface proteins that, instead of increasing or decreasing protein antigens, as happens with EGFR or other surface proteins driven by increased mRNA processing, produce surface molecules that are aberrant in nature and therefore more specific as targets to elicit a specific anti-tumor therapy. Here, EGFR is linked to neoplasm.